

# Pharmacological basis in the development of agents against myocardial ischemia



Institute of Pharmacology, College of Medicine,  
National Taiwan University, Taipei, Taiwan


8/5/2005

# Pathological Consequence of Reperfusion of Ischemic Myocardium

1. Excessive generation of free radical
2. Secondary injury of myocardium and coronary vessel
3. Severe cardiac arrhythmia
4. Sudden death
5. Remodel of myocardium

# Mechanisms of Ischemia and ischemia-reperfusion injury

1. Disturbance of cellular ion homeostasis including  $H^+$ ,  $Na^+$ , and  $Ca^{2+}$
2. Reduced ATP level
3. Increased oxidative stress
4. Increased electrical disturbance
5. Gap junction uncoupling
6. Release of inflammatory cytokines ( $TNF\alpha$ ,  $IL-1\beta$ ,  $IL-6$ ) and other inflammatory mediators(PAF)



# Object of Drug Treatment

1. Conversion of arrhythmia to normal rhythm
2. Prevention of reperfusion injury
3. Prevention of myocardial infarction
4. Prevention of progression of disease


# Ideal Therapeutic Agent

1. Exert antiarrhythmic activity dose-dependently
2. Inhibit myocardial infarction dose-dependently
3. Increase survival rate
4. Prevent progression of disease

# Methods for evaluation of drug effects on cardiac tissues

1. Effect on ionic currents of cardiac cells
2. Electrophysiological effect on Langendorf-perfused heart
3. Effect on chemical-induced arrhythmia
4. Effect on ischemia-induced arrhythmia
5. Effect on reperfusion-induced arrhythmia
6. Measurement of infarct zone
7. Measurement of cardiac function


# The electrophysiological effects of antiarrhythmic potential of a secoaporphine, N-allylsecoboldine



*Br. J. Pharmacol.* (1994), **113**, 221-227







# Mechanical and electrophysiological effects of 8-oxoberberine(JKL1073A) on atrial tissue




*British Journal of Pharmacology*(1996) 118,503-512


# 8-Oxoberberine prolong APD of Atrial cells by Inhibition of 4-AP Sensitive Potassium Outward Current



# Electrophysiological basis for antiarrhythmic efficacy, positive inotropy and low proarrhythmic potential of (-)-caryachine


**a**






Thaliporphine


# Effect of thaliporphine on cardiac tissues




# Effect of thaliporphine (10 $\mu$ M) on potassium outward current of rat ventricular cells



# Effect of thaliporphine (10 $\mu$ M) on potassium outward current of GP ventricular cells




# Effect of thaliporphine on copper-induced LDL peroxidation





# Superoxide anion scavenging activity of thaliporphine



# Effect of thaliporphine on ischemia-induced arrhythmias in the in vivo anesthetized rat

	<u>Ventricular tachycardia</u>		<u>Ventricular fibrillation</u>		Mortality (%)
	Incidence (%)	Duration (s)	Incidence (%)	Duration (s)	
Thaliporphine g/kg					
vehicle	100	36.8 ? 8.8	57	32.1 ? 8.9	29
$3.5 \times 10^{-7}$	60	16.1 ? 7.4	20	6.7 ? 4.9	0
$3.5 \times 10^{-6}$	50*	5.7 ? 3.3*	10	0.5 ? 0.5*	0
$3.5 \times 10^{-5}$	10*	0.3 ? 0.3*	0*	0.0 ? 0.0*	0

Values for duration of VT and VF are shown as the mean ? SE of 10-14 rats. \*Statistical difference at the level of  $p < 0.05$ , as compared with the vehicle. Vehicle is 0.01% DMSO in normal saline.

# Effect of thaliporphine and L-NAME + thaliporphine on myocardial infarct size caused by occlusion (4 hours) of the left coronary artery

	n	Area at risk (% of ventricle)	Necrotic (% of ventricle)	Necrotic (% of area at risk)
Thaliporphine g/kg				
vehicle	10	45.2 ? 1.0	19.8 ? 2.2	43.9 ? 5.1
$3.5 \times 10^{-7}$	9	47.0 ? 0.6	17.9 ? 2.3	38.1 ? 5.0
$3.5 \times 10^{-6}$	8	46.5 ? 0.9	13.4 ? 1.2*	29.0 ? 2.5*
$3.5 \times 10^{-5}$ (1)	11	46.9 ? 0.5	5.0 ? 0.9†	10.7 ? 1.8†
L-NAME g/kg				
$1 \times 10^{-3}$	9	47.5 ? 0.2	21.4 ? 3.5	45.1 ? 7.2
$1 \times 10^{-3}$ + (1)	8	47.0 ? 0.4	21.8 ? 4.0	46.5 ? 6.6


Data are presented as means ? SE; n, number of animals. \*  $p < 0.05$ , †  $p < 0.01$ , as compared with the vehicle. Vehicle is 0.01% DMSO in normal saline.

# Effect of thaliporphine on reperfusion-induced arrhythmias in the in vivo anesthetized rat

	<u>Ventricular tachycardia</u>		<u>Ventricular fibrillation</u>		Mortality (%)
	Incidence (%)	Duration (s)	Incidence (%)	Duration (s)	
Thaliporphine g/kg					
vehicle	100	17.4 ? 5.6	88	92.4 ? 20.5	75
$3.5 \times 10^{-7}$	86	28.6 ? 10.4	86	75.5 ? 15.6	43
$3.5 \times 10^{-6}$	57	14.6 ? 9.1	29*	9.2 ? 8.3*	0*
$3.5 \times 10^{-5}$	75	6.7 ? 2.9	13*	1.3 ? 1.3*	0*

Values for duration of VT and VF are shown as the mean ? SE of 10-14 rats. \*Statistical difference at the level of  $p < 0.05$ , as compared with the vehicle. Vehicle is 0.01% DMSO in normal saline.

# Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from *Fissistigma glaucescens*



*Br. J. Pharmacol.* (1996), 118, 1571-1583


# Effect of Liriodenine (NTU-105) on reperfusion-induced arrhythmias in the in vivo anesthetized rat

	VT		VF		Mortality (%)
	Incidence (%)	Duration (s)	Incidence (%)	Duration (s)	
Sham	—		—		—
Vehicle (4)	—		—		—
Operated	—		—		—
Vehicle (10)	100	65.55 ? 14.76	100	148.94 ? 47.19	80
NTU-105 $2.75 \times 10^{-9}$ g/kg (10)	100	52.57 ? 10.80	50	98.07 ? 49.48	40
NTU-105 $2.75 \times 10^{-8}$ g/kg (10)	100	35.47 ? 9.37	50	15.87 ? 9.48*	10
NTU-105 $2.75 \times 10^{-7}$ g/kg (10)	100	5.55 ? 1.84**	0	0.0 ? 0.0**	0

•<sup>a</sup> Vehicle is 0.1% DMSO in normal saline; (n), number of experiments; values for duration of VT and VF are shown as the mean ? S.E. Statistical difference at the level of \*  $P < 0.05$  and \*\*  $P < 0.01$ , as compared with vehicle.


A

Cell viability (% of control)



B

Apoptosis (fold increase of control)



SD  
NTU105 ( $\mu$ M)

—  
0

+  
0

+  
0.1

+  
1

SD  
NTU105 ( $\mu$ M)



—  
0

+  
0

+  
1

L-NAME  
+  
1


Q  
+  
0






## D: NTU-105


A




B




D: NTU-105







# Electrophysiological basis for the antiarrhythmic action and positive inotropy of HA-7, a furoquinoline alkaloid derivative, in rat heart






# Cardiac electrophysiologic and antiarrhythmic actions of a pavine alkaloid derivative, *O*-methyl-neocaryachine, in rat heart






**A****B**

# Effect of OMNCN on $I_{Na}$



# Effect of OMCN on potassium currents




## Ionic Mechanisms for the Antiarrhythmic Action of Cinnamophilin in Rat Heart



Ming-Jai Su<sup>a</sup> Wen-Pin Chen<sup>a</sup> Tase-Yueh Lo<sup>a</sup> Tian-Shung Wu<sup>b</sup>

<sup>a</sup>Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, and

<sup>b</sup>Department of Chemistry, National Chen-Kong University, Tainan, Taiwan




**Fig. 1.** Chemical structure of Cinn.




**Fig. 2.** Representative cardiac electrogram recorded from a low atrial recording electrode (lower panel) and a ventricular recording electrode (upper panel). Typical recordings obtained in control, ischemia, reperfusion and reperfusion plus treatment with 3  $\mu$ M Cinn. The ventricular tachycardia induced by ischemia-reperfusion was converted to normal sinus rhythm 3 min after cinnamophilin. A = Atrial depolarization; V = ventricular depolarization.

**Fig. 3.** Effects of Cinn on action potentials in the rat ventricular cell. **a-d** Action potentials (upper curve) and  $V_{max}$  (lower curve) in control, in the presence of 1 and 3  $\mu$ M Cinn and after washout of Cinn, respectively. The frequency of stimulation was 0.2 Hz.





Resveratrol




Astringinin


# Effect of resveratrol in rat ventricular myocyte

*0.1 mM EGTA in K<sup>+</sup> internal solution*

A





B



C

Action-potential clamp








# Resveratrol

Control


30  $\mu$ M

100  $\mu$ M




# Effect of astringinin on the action potential of rat ventricular myocyte


Control




3  $\mu$ M Astringinin





10  $\mu$ M







30  $\mu$ M



100  $\mu$ M





# Effect of Astringinin on Ischemia-Induced Arrhythmias in the in Vivo Anesthetized Rat

Astringinin (g/kg)	Ventricular tachycardia		Ventricular fibrillation		Mortality (%)
	Incidence (%)	Duration (s)	Incidence (%)	Duration (s)	
0 (vehicle)	100	38.1 ± 7.3	73	31.5 ± 12.4	36
$2.5 \times 10^{-6}$	100	32.4 ± 10.0	29	15.7 ± 10.2	29
$2.5 \times 10^{-5}$	50*	10.4 ± 3.2*	29	13.3 ± 6.2*	0
$2.5 \times 10^{-4}$	44*	5.7 ± 3.1*	11*	1.1 ± 1.1*	0

Values for duration of VT and VF are shown as the means ± SE of 7-11 rats. Vehicle is 0.01% DMSO in normal saline.

\*Statistical difference at the level of  $p < 0.05$

# Effect of Astringinin on Reperfusion-Induced Arrhythmias in the in Vivo Anesthetized Rat

Astringinin (g/kg)	Ventricular tachycardia		Ventricular fibrillation		Mortality (%)
	Incidence (%)	Duration (s)	Incidence (%)	Duration (s)	
0 (vehicle)	100	11.4 ± 5.3	100	87.0 ± 16.0	70
$2.5 \times 10^{-7}$	63	14.5 ± 5.9	50	29.6 ± 18.7	25
$2.5 \times 10^{-6}$	30	3.3 ± 2.3	10*	9.5 ± 9.5*	10*
$2.5 \times 10^{-5}$	25	6.0 ± 3.9	0*	0.0 ± 0.0*	0*

Values for duration of VT and VF are shown as the means ± SE of 8-10 rats. Vehicle is 0.01% DMSO in normal saline. \*Statistical difference at the level of  $p < 0.05$

# Conclusion

A. Antiarrhythmic mechanisms include

- Inhibition of ion channels
- Preservation of eNOS activity
- Antioxidant activity

B. Inhibition of ventricular fibrillation is correlated with the survival rate in animals



# Conclusion


- C. Inhibition of VT or VF don't necessarily lead to parallel decrease in myocardial injury or infarction.
- D. Agents with antioxidant and ion channel blocking activities don't always have better cardioprotective action in ischemia and ischemia/reperfusion animals .

# Conclusion


- E. Agents with both eNOS preservation and ion channel modulating activities have better protective action
- F. Both alkaloids and non-alkaloids can be a possible lead compounds as a useful myocardial protective agents

# Effect of E4031 on spontaneous action potential of HL-1 cell




Control



E4031 1  $\mu$ M



# The characteristics of $I_{Kr}$ in HL-1 cell





Thank you for your attention

